Clinical TrialJun 10, 2026, 04:02 PM
Tectonic Therapeutic Completes Enrollment in TX45 Phase 2 Trial
AI Summary
Tectonic Therapeutic, Inc. announced the completion of enrollment for its APEX Phase 2 clinical trial, evaluating the safety and efficacy of TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). The trial enrolled 191 patients globally, with a significant portion meeting criteria for a more severe disease subtype. Topline results are anticipated in early Q1 2027.
Key Highlights
- Tectonic Therapeutic completes enrollment for the APEX Phase 2 clinical trial evaluating TX45 in PH-HFpEF patients.
- The APEX trial enrolled 191 patients across 14 countries.
- Approximately 72% of enrolled patients (137) had CpcPH with PVR >3 WU at baseline.
- Mean baseline PVR in the overall population was 4.2 WU; in the CpcPH subset, it was 5.2 WU.
- Topline results from the APEX Phase 2 trial are expected in early Q1 2027.
Price Impact
More from TECX